Surgical Innovations Group PLC Issues Trading Update Amidst Flu Epidemic and NHS Strikes

Trading update: softer Q4 knocks Surgical Innovations’ 2025 revenue outlook

Surgical Innovations Group PLC has warned that fourth-quarter sales came in softer than expected, pulling full-year 2025 revenue down to c. £11.5 million with a commensurate hit to profits. The board has also increased its provision against slow-moving raw materials after a year-end inventory review.

The culprits are largely external: a global flu epidemic is reducing elective surgery volumes across key markets, UK NHS strikes have added capacity pressure, and a one-off quality issue at an OEM partner constrained December deliveries. Management says the quality issue has been addressed and normal shipments should resume in early 2026.

Net debt stood at £0.4 million as of 17 December 2025, and the company says it continues to closely monitor working capital. The board remains confident in the long-term demand for its reposable technology as healthcare systems pursue lower waste and reduced CO2 footprints.

What’s driving the Q4 slowdown?

Flu surge dents elective procedures across regions

The global flu epidemic is reducing the number of elective procedures – non-urgent surgeries that are often scheduled in advance – across Europe, APAC and the rest of the world. Fewer procedures mean less near-term demand for Surgical Innovations’ minimally invasive surgery products.

NHS industrial action compounds UK pressure

Further disruption came from NHS strikes. Industrial action in September and more strikes scheduled next week are creating additional delays in elective procedures and seasonal pressure on capacity. That combination would be expected to weigh on UK sales via Elemental Healthcare and broader adoption of the Group’s instruments and port access systems.

One-off OEM quality issue in December

December sales were also held back by a one-off quality issue linked to key components supplied by an OEM partner, which limited the Group’s ability to manufacture that partner’s product. The problem has been addressed, supply is resuming, and management expects normal deliveries to return in early 2026.

Key numbers and balance sheet snapshot

Expected FY2025 revenue	c. £11.5 million
Profit impact	Lower, commensurate with revenue reduction (not disclosed)
Inventory provision	Increased against slow-moving raw materials
Net debt (17 December 2025)	£0.4 million

Profit guidance beyond “commensurate” is not disclosed. There is no update on margins, cash flow, or segmental breakdowns in this release.

Why this matters for investors

• Temporary versus structural: The drivers here are largely temporary – flu and strikes – plus a one-off quality issue. That suggests a pathway to normalisation, particularly as OEM deliveries are expected to be back to normal early next year.
• Inventory and margin optics: Increasing provisions protects the balance sheet but will depress reported profits. It also hints at slower stock movement in some raw materials, which can pressure gross margins in the short term.
• Working capital watch: Net debt is modest at £0.4 million, but softer sales, inventory adjustments and OEM timing all make working capital management critical. Any recovery in elective procedures should help unwind this pressure.
• Sustainability tailwind: The board highlights growing focus on environmental sustainability. Surgical Innovations’ reposable portfolio – part reusable, part disposable – addresses waste and CO2 footprint, positioning the company well as procurement policies tilt greener.
• OEM execution risk: The December disruption underlines the importance of supplier quality and partner execution. The fix is in, but investors will want confirmation in early 2026 that deliveries and order intake are back on track.

Outlook heading into early 2026

The near-term narrative is cautious but not broken. If the flu wave subsides and NHS industrial action eases, elective procedure volumes should recover, helping core product demand. Management’s comment that OEM supply should normalise in early 2026 is also encouraging.

Longer term, the sustainability angle remains a differentiator. Reposable instruments offer cost-competitive solutions with lower plastic waste and a reduced CO2 footprint versus fully disposable alternatives. If buyers prioritise environmental outcomes in 2026 budgets, Surgical Innovations is well placed to benefit.

The swing factor is execution through the next two quarters: converting resuming supply into revenue, managing working capital tightly, and demonstrating margin resilience after the inventory provision.

What to watch at full-year results

• Revenue detail: Product and regional split to understand where demand softened most and where the rebound could be strongest.
• Margin impact: Gross margin drivers, including the size of the inventory provision and any cost recoveries from OEM disruptions.
• Cash and working capital: Year-end cash position, receivables and inventory levels, and commentary on net debt trajectory into Q1 2026.
• Order book and run-rate: Evidence that OEM deliveries have resumed and that elective procedure activity is normalising.
• Sustainability-led wins: Any new contracts or endorsements tied to environmental criteria supporting reposable adoption.

Jargon buster

• Elective procedures: Planned, non-urgent surgeries that can be rescheduled. These often dip during winter pressures or strikes.
• OEM partner: Original Equipment Manufacturer. Surgical Innovations designs or makes products for another company to sell under their brand.
• Inventory provision: An accounting charge recognising the risk that some stock is slow-moving or may not be sold at expected value.
• Reposable: A hybrid product design that is part reusable, part disposable, aiming to cut waste and emissions while remaining cost competitive.

My take: a disappointing Q4, but issues look manageable

This is not the year-end update anyone hoped for, but the drivers are mostly transitory. The flu epidemic and NHS strikes are powerful headwinds for any surgical supplier, and the OEM quality issue looks to be a one-off with a clear fix and a near-term timetable for normalisation.

The increase in inventory provisions will weigh on reported profits and is a reminder to watch gross margins. Net debt of £0.4 million suggests the balance sheet is not stretched, but working capital discipline will be key until volumes rebound.

In short, near-term caution, longer-term potential. If elective volumes recover and OEM deliveries normalise in early 2026, Surgical Innovations should be able to re-accelerate, with the sustainability proposition providing a supportive backdrop. I will be looking for concrete signs of that recovery at the full-year results.